GLAXOSMITHKLINE PHARMACEUTICAL

BSE: 500660 11 Nov 2025

Healthcare

₹ 2698.7

GlaxoSmithkline Pharmaceuticals Ltd. specializes in Pharmaceuticals within the Healthcare sector.

GLAXOSMITHKLINE PHARMACEUTICAL

BSE: 500660 11 Nov 2025

Healthcare

₹ 2698.7

GlaxoSmithkline Pharmaceuticals Ltd. specializes in Pharmaceuticals within the Healthcare sector.

Book Value

115.0

Dividend Yield

1.57%

Debt to Equity

0.01

Stock P/E

47.8

Market Cap

45,272 Cr

GLAXOSMITHKLINE PHARMACEUTICAL - Share Price & Details

Market Cap

₹45,272

High /Low

3,516 / 1,921

Stock P/E

47.8

Book Value

₹115.0

Dividend Yield

1.57

ROCE

63.2

ROE

₹46.9

Face Value

10.0

PEG Ratio

-2.44

EVEBITDA

₹32.4

Debt

9.95

CMP / FCF

59.1

Debt to equity

₹0.01

NP Ann

928

High price all time

3,516

Piotroski score

₹8.0

Graham Number

381.0

No. Eq. Shares

16.9

Net CF

₹475

Net profit

950

Price to book value

23.2

Interest Coverage

₹946.0

Low price all time

346.0

Industry PE

33.0

Reserves

₹1,782

Free Cash Flow

₹1,273

Broker Recommendations

Date	Author	Type	Reco Price	Target Price	Potential	Source	PDF Link
09 Nov 2025	ICICI Securities	Hold	₹2,590.55	₹2,500	0.9%	moneycontrol	View
02 Sep 2025	Deven Choksey	Buy	₹2,749.15	₹2,300	-17.1%	moneycontrol	View
02 Aug 2025	Motilal Oswal	Hold	₹2,933.9	₹3,000	4.5%	moneycontrol	View
27 May 2025	ICICI Securities	Sell	₹2,878.7	₹2,600	-8%	moneycontrol	View

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
FABINO ENTERPRISES LIMITED	NA	NA	NA	NA	5.09	84.8
Triochem Products Ltd.,	2.21	-0.31	NA	-1.25	0
GLAXOSMITHKLINE PHARMACEUTICAL	10135.1	2574.9	9799.4	15.2	45,272	47.8
Laurus Labs Limited	14542.7	1579.4	14327.5	2.93	44930	88.3
Narayana Hrudayalaya Limited	9595.77	873.71	9431.41	4.3	35252	44.6

Peer Comparison Chart

About GLAXOSMITHKLINE PHARMACEUTICAL

GlaxoSmithkline Pharmaceuticals Ltd., with Security Code 500660, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Order Book

Latest News

Glaxosmithkline Pharmaceuticals Faces Market Evaluation Shift Amid Stabilizing Performance Metrics

(26 Sep 2025)

Glaxosmithkline Pharmaceuticals has recently adjusted its evaluation, indicating a shift in market position and technical indicators.

Is Weakness In GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

(03 Sep 2025)

It is hard to get excited after looking at GlaxoSmithKline Pharmaceuticals' (NSE:GLAXO) recent performance, when its...

Quarterly Table

Standalone Consolidated

Metrics	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Sep 2025	Sep 2025	Sep 2025	Sep 2025	Sep 2025	Sep 2025
Sales	946.4	966.1	804.8	973.6	973.6	973.6	973.6	973.6	973.6	973.6
Expenses	656.2	635.3	554.1	639.0	639.0	639.0	639.0	639.0	639.0	639.0
Operating Profit	290.2	330.8	250.8	334.7	334.7	334.7	334.7	334.7	334.7	334.7
OPM %	30.66%	34.24%	31.16%	34.37%	34.37%	34.37%	34.37%	34.37%	34.37%	34.37%
Other Income	35.1	39.5	43.8	33.9	33.9	33.9	33.9	33.9	33.9	33.9
Interest	0.1	0.6	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Depreciation	18.8	14.7	15.5	17.4	17.4	17.4	17.4	17.4	17.4	17.4
Profit before tax	306.4	354.9	278.6	348.0	348.0	348.0	348.0	348.0	348.0	348.0
Tax %	25.4%	-26.7%	26.5%	27.3%	27.3%	27.3%	27.3%	27.3%	27.3%	27.3%
Net Profit	228.6	260.1	204.7	255.0	255.0	255.0	255.0	255.0	255.0	255.0
EPS in Rs	13.49	0	12.08	15.06	15.06	15.06	15.06	15.06	15.06	15.06

Metrics	Sep 2024	Dec 2024	Mar 2025	Sep 2025	Sep 2025	Sep 2025	Sep 2025	Sep 2025	Sep 2025	Sep 2025
Sales	1,010.8	949.4	974.4	979.9	979.9	979.9	979.9	979.9	979.9	979.9
Expenses	689.1	657.5	641.1	644.2	644.2	644.2	644.2	644.2	644.2	644.2
Operating Profit	321.7	291.9	333.3	335.7	335.7	335.7	335.7	335.7	335.7	335.7
OPM %	31.83%	30.75%	34.2%	34.26%	34.26%	34.26%	34.26%	34.26%	34.26%	34.26%
Other Income	39.2	35.1	40.7	36.2	36.2	36.2	36.2	36.2	36.2	36.2
Interest	0.3	0.1	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Depreciation	16.9	18.8	14.7	17.4	17.4	17.4	17.4	17.4	17.4	17.4
Profit before tax	339.1	308.1	358.7	351.4	351.4	351.4	351.4	351.4	351.4	351.4
Tax %	-26.6%	-25.4%	-26.7%	27.3%	27.3%	27.3%	27.3%	27.3%	27.3%	-27.3%
Net Profit	252.5	229.9	262.9	257.5	257.5	257.5	257.5	257.5	257.5	257.5
EPS in Rs	14.91	13.57	0	15.2	15.2	15.2	15.2	15.2	15.2	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	1%
5 Years:	3%
3 Years:	5%
TTM:	9%

Compounded Profit Growth
10 Years:	6%
5 Years:	36%
3 Years:	-18%
TTM:	41%

Stock Price CAGR
10 Years:	7%
5 Years:	17%
3 Years:	25%
1 Year:	22%

Compounded Sales Growth
10 Years:	1%
5 Years:	3%
3 Years:	5%
TTM:	9%

Compounded Profit Growth
10 Years:	6%
5 Years:	36%
3 Years:	-18%
TTM:	41%

Stock Price CAGR
10 Years:	7%
5 Years:	17%
3 Years:	25%
1 Year:	22%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Stock Mutual Funds Data

Order Book

News Date ▲▼	Headline ▲▼	Issuer Entity ▲▼	Issuer Type ▲▼	Order Size ▲▼	Time Period ▲▼
Loading company updates…

Loading technicals…

Moving Averages

Latest Close: — • Records Used: — • Last Trading Date: —

Simple Moving Averages (SMA)

Period	SMA Value	Status

Exponential Moving Averages (EMA)

Period	EMA Value	Status

Oscillators

Key Oscillators

latest calculation

Indicator	Value

GLAXOSMITHKLINE PHARMACEUTICAL

GLAXOSMITHKLINE PHARMACEUTICAL

GLAXOSMITHKLINE PHARMACEUTICAL - Share Price & Details

Broker Recommendations

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About GLAXOSMITHKLINE PHARMACEUTICAL

Order Book

Latest News

Glaxosmithkline Pharmaceuticals Faces Market Evaluation Shift Amid Stabilizing Performance Metrics

Is Weakness In GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

GSK Pharma re-enters oncology market

GSK Pharma forays into gynaecological cancer treatment in India

GSK re-enters India’s cancer drug market

GSK Pharma Shares Up 1% on Entry Into Gynaecological Cancer Treatment in India

Glaxosmithkline Pharmaceuticals Outperforms Sector Amid Mixed Moving Average Trends

Glaxosmithkline Pharmaceuticals Adjusts Evaluation Amid Shifting Market Sentiment and Performance Metrics

Glaxosmithkline Pharmaceuticals Faces Continued Stock Decline Amid Broader Market Weakness

GlaxoSmithKline Pharmaceuticals Limited Just Missed Revenue By 8.6%: Here's What Analysts Think Will Happen Next

GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) Q1 2026 Earnings Call Highlights: Strategic ... By GuruFocus

Glaxosmithkline Faces Significant Stock Decline Amid Broader Market Trends

GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr

GSK Pharma Q1FY26 Profit Up 12.7% YoY; Stock Falls 7.5%

Glaxosmithkline Pharmaceuticals Reports Decline in Key Financial Metrics for June 2025

India's GlaxoSmithKline Pharma posts first revenue drop in over two years

GSK Pharma Q1 results: PAT rises 12% to ₹279 cr, income declines marginally

GSK Pharma on track to bring in its oncology products Jemperli and Zejula

GlaxoSmithKline Pharmaceuticals (NSEI:GLAXO) - Stock Analysis

Jiangsu Hengrui Pharmaceuticals Partners with GSK for Global Licensing Agreement

Technical Analysis: GlaxoSmithKline Pharmaceuticals Limited (500660) - Market-beating returns

Can GlaxoSmithKline Pharmaceuticals Limited (500660) Maintain Its Valuation - Free Investment Community

Would You Accumulate or Wait on GlaxoSmithKline Pharmaceuticals Limited (500660) - Accelerated wealth expansion

Bullish Pattern Emerging on GlaxoSmithKline Pharmaceuticals Limited (500660) - Free Investment Timing Strategies

GlaxoSmithKline Pharmaceuticals Limited (500660) Stock Rallies - Free Investment Case Studies

GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) stock price dropped 4.3% last week; public companies would not be happy

Glaxosmithkline Pharmaceuticals Adjusts Technical Outlook Amid Strong Year-to-Date Performance

GlaxoSmithKline Pharmaceuticals appoints Vishwanath Swarup as Commercial Head - General Medicines

Employees of GSK from 2011 to 2024, by world region

Healthcare giant GSK Pharma to invest Rs 1K cr in Karnataka plant

GlaxoSmithKline Pharmaceuticals declare Quarterly Result

GlaxoSmithKline Receives Rs. 3.36 Cr GST Demand Order

We Take A Look At Whether GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) CEO May Be Underpaid

Pharma Stocks Tumble; Sigachi Industries Tanks Nearly 7 %

Glaxosmithkline Pharmaceuticals Achieves 52-Week High Amid Strong Financial Performance

Glaxosmithkline Pharmaceuticals - At multi-year highs: These 7 stocks witness 5-year swing high breakout

Glaxosmithkline Pharmaceuticals Shows Strong Market Performance Amid Sector Gains

Glaxosmithkline Reaches 52-Week High Amid Broader Market Challenges and Strong Fundamentals

Rs 159 Dividend Stocks: 14 companies' shares to trade ex-date today (May 30, Friday) – Full List

Glaxosmithkline Pharmaceuticals Faces Short-Term Decline Amid Strong Yearly Performance

GlaxoSmithKline Pharmaceuticals Shares Rise by 2.21% in Today's Session

GRSE and 3 Other Stocks Trading at All-Time Highs to Keep on Your Radar

Read This Before Considering GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Upcoming ₹42.00 Dividend

Pharma shares in focus; GSK, Jubilant, Eris, Gland, Torrent rally up to 8%

Fire disrupts production at GSK Pharma's contract manufacturing site

Fire at GSK Pharma site, production disrupted

Fire in GSK Pharma unit disrupts production

Earnings Update: Here's Why Analysts Just Lifted Their GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Price Target To ₹3,072

Rs 42 dividend per share: Record date fixed by pharma company in Q4 results 2025

Abbott India's quarterly profit climbs 28% on strong demand

Glaxosmithkline Pharmaceuticals standalone net profit rises 34.73% in the March 2025 quarter

Glaxosmithkline Pharmaceuticals consolidated net profit rises 35.17% in the March 2025 quarter

Pharma stock jumps 8% after company’s net profit increases by 36% YoY

Here's why GSK Pharma share price was buzzing in trade on Wednesday, May 14

gsk pharma gains as q4 pat rises 35 yoy to rs 260 cr; declares dividend of rs 42share

GSK Pharma Q4 profit rises 35% to ₹263 crore on strong brand growth

GlaxoSmithKline Pharmaceuticals AGM scheduled

Glaxosmithkline Pharmaceuticals Shows Resilience Amid Broader Market Decline

GSK Pharma Share Price Rises 1.62% in Early Trade – What’s Next? | May 2025

India's GlaxoSmithKline Pharma reports profit rise on strong demand

GlaxoSmithKline Pharma Q4 Results: Profit Up 36% At Rs 263 Crore

GSK Pharma Q4 Results: Net profit at ₹260 crore; ₹42 dividend declared

Board of GlaxoSmithKline Pharmaceuticals recommends final dividend

Glaxosmithkline Reports Strong Financial Results, Highlighting Increased Profitability and Efficiency in March 2025

Glaxosmithkline Faces Recent Stock Volatility Amid Broader Market Decline

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) shareholders have earned a 18% CAGR over the last five years

Acyclovir Industry Market is Thriving Worldwide GlaxoSmithKline plc, Teva Pharmaceutical Industries

GSK Pharma names Sukanya Choudhury as Regulatory Head, Growth Emerging Markets

Glaxosmithkline Pharmaceuticals Faces Potential Trend Reversal Amid Broader Market Decline